Documents
Application Sponsors
ANDA 214921 | MSN LABORATORIES PRIVATE LTD | |
Marketing Status
None (Tentative Approval) | 001 |
None (Tentative Approval) | 002 |
None (Tentative Approval) | 003 |
None (Tentative Approval) | 004 |
None (Tentative Approval) | 005 |
Application Products
002 | TABLET;ORAL | 25MG | 0 | BRIVARACETAM | BRIVARACETAM |
003 | TABLET;ORAL | 50MG | 0 | BRIVARACETAM | BRIVARACETAM |
004 | TABLET;ORAL | 75MG | 0 | BRIVARACETAM | BRIVARACETAM |
005 | TABLET;ORAL | 100MG | 0 | BRIVARACETAM | BRIVARACETAM |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2022-04-20 | STANDARD |
Submissions Property Types
CDER Filings
MSN LABORATORIES PRIVATE LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 214921
[companyName] => MSN LABORATORIES PRIVATE LTD
[docInserts] => ["",""]
[products] => [{"drugName":"BRIVARACETAM","activeIngredients":"BRIVARACETAM","strength":"10MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"BRIVARACETAM","activeIngredients":"BRIVARACETAM","strength":"25MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"BRIVARACETAM","activeIngredients":"BRIVARACETAM","strength":"50MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"BRIVARACETAM","activeIngredients":"BRIVARACETAM","strength":"75MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"BRIVARACETAM","activeIngredients":"BRIVARACETAM","strength":"100MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"04\/20\/2022","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2022-04-20
)
)